Evaluating new ways to treat tree nut allergies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The TRADE trial focuses on assessing the efficacy and safety of sublingual immunotherapy and lower doses of oral immunotherapy for individuals with tree nut allergies. This randomized controlled trial aims to determine if these alternative methods can provide a more tolerable treatment option compared to current standards. Participants will be monitored for their allergic reactions and overall response to the treatment. The study seeks to improve the management of tree nut allergies through innovative immunotherapy approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Allergic to tree nut with baseline threshold of 444 mg protein or less and provides consent, and where applicable, assent.

Exclusion Criteria:

1. History of anaphylaxis to tree nut severe enough to cause shock, syncope, or intubation
2. Eosinophilic or other inflammatory gastrointestinal disease within the past 2 years
3. Severe (GINA severity class 5) or uncontrolled asthma including exacerbation within past 6 months
4. Use of biologics, other food immunotherapy or experimental treatment in past 6 months.
5. Ongoing other allergic diseases severe enough to preclude discontinuing antihistamines for 7 days prior to assessment visits
6. Pregnancy or significant medical condition (e.g., liver, kidney, gastrointestinal, cardiovascular, hematologic, or pulmonary disease; allergy to the oat-based placebo) which would put the participant at excessive risk for food allergic reactions as judged by local investigator

Where it's running

• McMaster University Medical Centre
  Hamilton, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Derek Chu, MD PhD FRCPC — Hamilton Health Sciences & McMaster University
• Study coordinator: Heather Le
• Email: lehea@hhsc.ca
• Phone: 905-521-2100

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating food allergy thresholds and predictors

  This study is trying to see how much of certain foods can trigger allergic reactions in people with food allergies in Canada and what factors might affect how severe those reactions are.

  Recruiting Hamilton Health Sciences Corporation · Hamilton, Ontario · NCT06038019

• Oral Food Challenge After Starting Omalizumab in Food Allergy

  This trial tests whether omalizumab begins to help with food allergy within 2 to 4 weeks after starting treatment in people with a confirmed food allergy.

  Recruiting Phase 4 Johns Hopkins University · Baltimore, Maryland · NCT07845552

• Early Introduction of Allergenic Foods in Infants With Extra Support

  This study tests whether giving families educational materials alone or with extra in-person or live-stream support helps parents introduce known allergenic foods to their infants earlier.

  Recruiting Stanford University · Stanford, California · NCT07321522

• EmoTIChealth: a serious game to strengthen emotional skills in teens with and without chronic conditions

  This project will try a digital serious game for 12–16-year-olds to boost socioemotional skills and offer tailored support for teens with asthma, food allergy, type 1 diabetes, or allergic rhinitis.

  Recruiting University of Valencia · Valencia, Valencia · NCT07212530

• Omalizumab given by weight for food allergy

  This study will test whether higher, weight-based doses of omalizumab are safe and help people with food allergies, including those with very high allergic antibody (IgE) levels, tolerate their allergens better.

  Recruiting at 3 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT06943534

• Oral immunotherapy for children with cashew nut allergies

  This study tests if giving cashew nuts in small amounts can help children with cashew nut allergies build tolerance and reduce their allergic reactions.

  Recruiting HUS Skin and Allergy Hospital · Helsinki · NCT06930950

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.